XML 83 R49.htm IDEA: XBRL DOCUMENT v3.5.0.2
Intangible Assets and Goodwill (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Dec. 31, 2015
Intangible assets          
Total intangible assets, gross $ 7,710.3   $ 7,710.3   $ 7,646.3
Accumulated Amortization (3,742.7)   (3,742.7)   (3,561.2)
Intangible assets, net 3,967.6   3,967.6   4,085.1
Intangible Assets and Goodwill (Textual) [Abstract]          
Amortization of acquired intangible assets 92.9 $ 92.0 181.7 $ 187.9  
Accumulated impairment losses related to goodwill 0.0   0.0    
Expected future amortization expense, 2016 (remaining six months) 181.6   181.6    
Expected future amortization expense, 2017 325.1   325.1    
Expected future amortization expense, 2018 298.2   298.2    
Expected future amortization expense, 2019 282.7   282.7    
Expected future amortization expense, 2020 277.1   277.1    
Expected future amortization expense, 2021 265.0   265.0    
Out-licensed patents          
Intangible assets          
Cost 543.3   543.3   543.3
Accumulated Amortization (514.9)   (514.9)   (506.0)
Net 28.4   $ 28.4   37.3
Out-licensed patents | Minimum          
Intangible assets          
Estimated life, (in years)     13 years    
Out-licensed patents | Maximum          
Intangible assets          
Estimated life, (in years)     23 years    
Developed technology          
Intangible assets          
Cost 3,005.3   $ 3,005.3   3,005.3
Accumulated Amortization (2,604.5)   (2,604.5)   (2,552.9)
Net 400.8   $ 400.8   452.4
Developed technology | Minimum          
Intangible assets          
Estimated life, (in years)     15 years    
Developed technology | Maximum          
Intangible assets          
Estimated life, (in years)     23 years    
Developed technology | AVONEX          
Intangible assets          
Net 392.8   $ 392.8    
Acquired and in-licensed rights and patents          
Intangible assets          
Cost 3,405.4   3,405.4   3,303.2
Accumulated Amortization (623.3)   (623.3)   (502.3)
Net 2,782.1   $ 2,782.1   2,800.9
Acquired and in-licensed rights and patents | Minimum          
Intangible assets          
Estimated life, (in years)     6 years    
Acquired and in-licensed rights and patents | Maximum          
Intangible assets          
Estimated life, (in years)     18 years    
Acquired and in-licensed rights and patents | Biosimilars          
Intangible assets          
Increase in acquired and in-licensed rights and patents 25.0   $ 50.0    
Acquired and in-licensed rights and patents | ZINBRYTA          
Intangible assets          
Increase in acquired and in-licensed rights and patents     20.0    
Acquired and in-licensed rights and patents | ALPROLIX          
Intangible assets          
Increase in acquired and in-licensed rights and patents     26.5    
Contingent payment made during the period     20.0    
Deferred tax liability 6.5   $ 6.5    
In-process research and development          
Intangible assets          
Indefinite lived intangible assets useful life     Indefinite until commercialization    
Cost and Net 692.3   $ 692.3   730.5
Accumulated Amortization 0.0   $ 0.0   0.0
Trademarks and trade names          
Intangible assets          
Indefinite lived intangible assets useful life     Indefinite    
Cost and Net 64.0   $ 64.0   64.0
Accumulated Amortization 0.0   0.0   $ 0.0
TYSABRI product | Acquired and in-licensed rights and patents          
Intangible assets          
Net $ 2,633.4   $ 2,633.4